Nafamostat Efficacy in Phase 3 Registrational CRRT Study
← catalyst calendarSponsored by Talphera, Inc (industry) · TLPH — their whole pipeline →.
Phase
Not applicable
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
70estimated
Sites
10
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-08-15 | actual | When the study began enrolling |
| Primary completion | Dec 2025 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2025 | estimated | The whole study's end, after follow-up |
| First posted | 2023-11-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-10-15 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Acute Kidney Injury
Interventions
- Device: Niyad (nafamostat mesylate)
- Device: Placebo (0.9% NaCl)
Primary outcome
what the primary-completion date above is the date OFmean post-filter activated clotting time (ACT)
measured 24 hours
Permalink · TLPH's whole pipeline · Catalyst calendar · Every registered study · What changed